Recent Research Analysts’ Ratings Changes for Perspective Therapeutics (CATX)

by · The Cerbat Gem

A number of research firms have changed their ratings and price targets for Perspective Therapeutics (NYSE: CATX):

  • 4/7/2025 – Perspective Therapeutics had its price target lowered by analysts at Truist Financial Co. from $21.00 to $10.00. They now have a “buy” rating on the stock.
  • 3/31/2025 – Perspective Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 3/27/2025 – Perspective Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $15.00. They now have an “outperform” rating on the stock.
  • 3/26/2025 – Perspective Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
  • 3/19/2025 – Perspective Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
  • 3/17/2025 – Perspective Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
  • 3/13/2025 – Perspective Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $10.00 price target on the stock.
  • 3/10/2025 – Perspective Therapeutics was upgraded by analysts at Brookline Capital Management to a “strong-buy” rating.
  • 3/7/2025 – Perspective Therapeutics is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $15.00 price target on the stock.
  • 3/6/2025 – Perspective Therapeutics was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
  • 3/4/2025 – Perspective Therapeutics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.

Perspective Therapeutics Stock Down 2.1 %

Shares of Perspective Therapeutics stock traded down $0.04 during trading on Thursday, hitting $1.86. 1,726,219 shares of the stock were exchanged, compared to its average volume of 1,026,748. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $19.05. The company has a fifty day moving average price of $2.58 and a 200-day moving average price of $5.57.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Robert F. Williamson III acquired 38,145 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were purchased at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now directly owns 108,982 shares in the company, valued at approximately $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Juan Graham acquired 33,333 shares of the company’s stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This trade represents a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 115,696 shares of company stock worth $256,344 over the last 90 days. Company insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of CATX. Deerfield Management Company L.P. Series C grew its stake in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after acquiring an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares in the last quarter. State Street Corp increased its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the period. Nicholson Wealth Management Group LLC raised its position in shares of Perspective Therapeutics by 0.4% in the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after buying an additional 7,000 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after buying an additional 800,000 shares during the period. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Read More